McGuinness Ryan
MDS Analytical Technologies, Drug Discovery, 1311 Orleans Drive, Sunnyvale, CA 94089, United States.
Curr Opin Pharmacol. 2007 Oct;7(5):535-40. doi: 10.1016/j.coph.2007.08.004. Epub 2007 Sep 27.
Cell-based assays are continuing to grow in importance in the drug discovery workflow. Their early introduction holds the promise of limiting attrition in the later, more costly phases of the process. This article reviews recent advances in the development of impedance technologies for label-free cell-based assays. These systems are capable of monitoring endogenous receptor activation, and thus generate more physiologically relevant measures of pharmacological endpoints. Primary cells can be investigated as well, thus producing disease relevant information. Label-free assays significantly decrease assay development efforts and avoid many complications inherent in recombinant readout systems. Impedance-based systems have great potential to advance the utility of cell-based assays as they are applied to drug discovery and pharmacology.
基于细胞的检测方法在药物发现流程中的重要性持续增加。早期引入这些方法有望在后续成本更高的阶段减少损耗。本文综述了用于无标记基于细胞检测的阻抗技术开发的最新进展。这些系统能够监测内源性受体激活，从而生成更具生理学相关性的药理学终点指标。原代细胞也可进行研究，进而产生与疾病相关的信息。无标记检测显著减少了检测方法开发的工作量，并避免了重组读出系统中固有的许多复杂问题。基于阻抗的系统在应用于药物发现和药理学时，具有极大的潜力来提升基于细胞检测的效用。
